This effectively killed the common use of droperidol and made way for heavy usage of the much more expensive non-generic 5-HT3 serotonin receptor antagonists on the market even though these newer drugs had also been shown to prolong QTc as much, if not more than droperidol.
This effectively killed the common use of droperidol and made way for heavy usage of the much more expensive non-generic 5-HT3 serotonin receptor antagonists on the market. Interestingly, these newer drugs had also been shown to prolong QTc as much, if not more than droperidol.